The purpose of this study is to evaluate the treatment of a cancerous disease of the peritoneum with complete cytoreductive surgery with intraperitoneal chemohyperthermia using oxaliplatin plus irinotecan.

This is a Phase II study with 100 patients. Origins of the tumors: these include colon, rectum, appendix, peritoneum, and endocrine tumors.

Inclusion Criteria:

• Peritoneal seedings coming from colon, rectum, pseudomyxoma (appendix), peritoneum (mesothelioma and serous tumors), or endocrine tumors.
• No extra-abdominal metastases
• Good general status (American Society of Anesthesiologists Physical Status score [ASA] 1 or 2)
• Signed consent

Exclusion Criteria:

• Tumor seedings coming from other origins
• Huge peritoneal carcinomatosis (peritoneal score > 25, except for pseudomyxomas)
• Peritoneal carcinomatosis progressing rapidly
• Presence of extra-abdominal metastases
• Patients presenting contraindications to the use of oxaliplatin or irinotecan